Neurotrophic peptides
AssigneeThe Research Foundation for Mental Hygiene, Inc.
InventorsKhalid Iqbal, Inge Grundke-Iqbal
Life of this patent
Estimating the term…
Abstract
The present invention relates to a neurotrophic peptide having an amino acid sequence of VGDGGLFEKKL (SEQ ID NO: 1) and alternatively comprising an adamantyl group at the C-and/or N-terminal end. The neurotrophic peptide can rescue cognition, correct impairments in neural cell proliferation and synaptic plasticity, and thus address the cognitive defects associated with Alzheimer's disease.
Claims11
A method of treating a subject having Alzheimer's disease comprising the step of administering a therapeutic amount of a neurotrophic peptide consisting of the amino acid sequence selected from the group consisting of VGDGGLFEKKL (SEQ ID NO:
- 1), GDGGLFEK (SEQ ID NO:
- 5), GLFEKKLW (SEQ ID NO:
- 6), VGDG (SEQ ID NO:
- 7), GDGG (SEQ ID NO:
- 8), DGGL (SEQ ID NO:
- 9), and GGLF (SEQ ID NO:
- 10).
A method of treating a subject having Alzheimer's disease comprising the step of administering a therapeutic amount of a neurotrophic peptide consisting of the amino acid sequence DGGL (SEQ ID NO:
- 9) bound to an adamantane building block.
Dependencies are inferred from the claim text.